Covance: New offering applies Chiltern-developed engagement models
“These client segments have specific needs for their clinical trials, which can be different from those of larger biopharma companies,” said Lewis Cameron, head of Global Clinical Development, Covance.
The offering applies “customized engagement models successfully developed by Chiltern,” he told us.
Chiltern joined Covance, the drug development division of LabCorp, after being acquired in September 2017 for $1.2bn.
The new dedicated offering, announced Monday, also provides access to additional resources provided by Covance and LabCorp, said Cameron, and includes access to the Covance MarketPlace, the company’s proprietary model for connecting biotech companies with co-development or investment partners.
Cameron explained the addition of Chiltern strengthened Covance’s “focus on the biotech client segment and deepened our therapeutic expertise, particularly in oncology.”
“Chiltern also brought comprehensive capabilities in medical device development,” he said, explaining that the company is “pleased” with the progress of the Chiltern integration to date.
“This offering demonstrates how we’re working to translate the powerful combination of Covance and Chiltern to benefit our clients.”
